Ironwood Pharmaceuticals Reports First Quarter 2025 Results
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Reports-First-Quarter-2025-Results/default.aspx
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-to-Participate-in-The-Citizens-Life-Sciences-Conference/default.aspx
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Reiterates-Full-Year-2025-LINZESS-U-S–Net-Sales-Guidance-and-Raises-Adjusted-EBITDA-Guidance/default.aspx
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-to-Present-Real-World-Data-at-Digestive-Disease-Week-2025-on-Adoption-of-New-Diagnosis-Codes-Among-Short-Bowel-Syndrome-Patients-Who-Are-Dependent-on-Parenteral-Support/default.aspx
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Provides-Clinical-and-Regulatory-Update-on-Apraglutide/default.aspx
Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Announces-Receipt-of-Nasdaq-Non-Compliance-Notification-Regarding-Late-2024-Form-10-K-Filing/default.aspx
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2024-Results-Achieves-2024-Financial-Guidance/default.aspx
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2024-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Initiates-Apraglutide-NDA-Submission-Highlights-Compelling-New-Data-and-Updates-Corporate-Structure-to-Position-for-the-Future/default.aspx
Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Participate-in-the-Piper-Sandler-36th-Annual-Healthcare-Conference/default.aspx
